Analysis of T Cell Receptor Repertoire

SK2012-042

Summary of Invention

The investigators have developed a novel method of directly measuring human T Cell Receptor (TCR) diversity with high resolution and accuracy.

A diverse TCR repertoire is capable of recognizing a broad range of antigens present on pathogens and is a necessary component of an effective immune system. Knowing a patient’s exact TCR repertoire would allow researchers and clinicians to conduct immune profiling on patients whose system is compromised and to monitor disease states over the course of therapy. Additionally, such knowledge could lead to the development and adoption of strategies that improve T cell reconstitution, greatly reducing transplant-associated morbidity and mortality and the health risks associated with other auto-immune diseases.

Advantages

  • This technology combines two techniques, 5′ RACE PCR and deep sequencing, in order to determine TCR repertoire complexity with great precision. This novel approach allows for a more accurate measure of T cell receptors than currently used methods, which only provide a rough estimate of repertoire complexity.
  • This method can also assess the entire TCR-β repertoire using a single oligonucleotide pair, thereby eliminating amplification bias and the resulting inaccuracy often associated with PCR.

Market Opportunities

With a potential market as a research tool or diagnostic, this method can be used to characterize the immunity of a patient provided by T cells in clinical settings of allo-HSCT, immune deficiency, autoimmunity, and tumor immunity.

Areas of Application

Monitoring immune state

Patent Information

PCT application entitled “Quantitative Assessment of Human T-Cell Repertoire Recovery After Allogeneic Hematopoietic Stem Cell Transplantation” filed on July 13th, 2013

Lead Investigator

Dr. Eric Pamer, MD, Laboratory Head, Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering
 

Contact Information

Yashodhara Dash, MBBS, PhD, MBA
Senior Manager, Technology Management and Commercialization
Tel: 646-888-1073

 

Stage of Development
Ready to use
Technology Types